December 16, 2009 (FinancialWire) (Investrend Broadcast Syndicate) — Santarus, Inc. (NASDAQ: SNTS) webcast their Lippert/Heilshorn Life Sciences Conference presentation yesterday. A recording of that presentation is now available (via http://infoescrow.net/f/?u=http://www.investorcalendar.com/IC/ClientPage.asp?ID=153292).

Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of traveler’s diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry. Santarus was founded in 1996 and is based in San Diego, California.

The company’s current market capitalization is approximately US$ 266.6 million. SNTS’s stock last closed at US$ 4.78 per share.

Other recently webcast company presentations, financial results & earnings calls now available through VCall/WILink include LocatePLUS Holdings, Inc. (OTC: LPHC), Rentech, Inc. (AMEX: RTK), CytRx Corp. (NASDAQ: CYTR) and ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX). Recordings are accessible via the search function at http://infoescrow.net/f/?u=http://www.investorcalendar.com by entering any company’s ticker symbol into the search field.

Recently issued annual reports and company filings available through WILink (http://investrend.ar.wilink.com/?level=279) include Niusule Biotech Corp. (OTCBB: NIUS), JPMorgan European Investment Trust PLC (LSE: JFF), Ecofin Water & Power Opportunities PLC (LSE: ECWO), Invesco Property Income Trust Ltd. (LSE: IPI), Hansa Trust PLC (LSE: HAN) (OTC: FSBTF), Perpetual Income & Growth Investment Trust PLC (LSE: PLI), New India Investment Trust PLC (LSE: NII), JPMorgan Fleming Smaller Japanese Companies Investment Trust PLC (LSE: JPS), Edinburgh Investment Trust PLC (LSE: EDIN) (OTC: EHITF) and Armour Group PLC (LSE: AMR).

(Source for company description: Santarus, Inc.)

FinancialWire(tm) provides complete, daily conference call schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “Daily FirstAlert(tm)” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php).  Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[wreiq] [wbcstsc] [wilnknli]